Larimar Therapeutics, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 36.95 million compared to USD 35.36 million a year ago. Basic loss per share from continuing operations was USD 0.84 compared to USD 1.37 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8 USD | +12.68% | +12.99% | +75.82% |
May. 31 | Health Care Stocks Climb On Drug News -- Health Care Roundup | DJ |
May. 31 | Larimar Therapeutics Shares Rise 15% Nomlabofusp Selected for FDA Program | DJ |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+75.82% | 510M | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.82% | 21.96B | |
-10.12% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B | |
+77.64% | 8.87B |
- Stock Market
- Equities
- LRMR Stock
- News Larimar Therapeutics, Inc.
- Larimar Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023